C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi, John H Alexander, A Michael Lincoff, Mark Heise, Pierluigi Tricoci, Lawrence I Deckelbaum, Sojaita Jenny Mears, Jose C Nicolau, Renato D Lopes, Bela Merkely, Basil S Lewis, Jan H Cornel, Jaroslaw Trebacz, Alexander Parkhomenko, Peter Libby, Frank M Sacks, Thomas J Povsic, Marc Bonaca, Shaun G Goodman, Deepak L Bhatt, Michal Tendera, P Gabriel Steg, Paul M Ridker, Philip Aylward, John J P Kastelein, Christoph Bode, Kenneth W Mahaffey, Stephen J Nicholls, Stuart J Pocock, Roxana Mehran, Robert A Harrington
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear...
April 6, 2024: New England Journal of Medicine